Bone Biologics EBIT per Share
The EBIT per Share of Bone Biologics (BBLG) as of Oct 16, 2026 is -2.75 USD. In the previous year, EBIT per Share was -1.43 USD — a change of 92.78% (lower).
Get this data via API
Financial Data API
EBIT per Share
-2.75USD
YoY
92.78%
Last updated:
The Bone Biologics EBIT per Share history
3 Years
10 Years
25 Years
Max
| YEAR | EBIT per Share | YoY |
|---|---|---|
| est | -2.69USD | +3.44% |
| est | -2.60USD | -5.66% |
| -2.75USD | +92.78% | |
| -1.43USD | -93.05% | |
| -20.54USD | -64.25% | |
| -57.45USD | +124.79% | |
| -25.56USD | +94,944.85% | |
| -0.03USD | -99.94% | |
| -47.89USD | -87.47% | |
| -382.34USD | +56,052.86% | |
| -0.68USD | -99.98% | |
| -2,746.79USD | +882.30% | |
| -279.63USD | +118,730.81% | |
| -0.24USD | +75.09% | |
| -0.13USD | +12,746.49% | |
| -0.00USD | +74.37% | |
| -0.00USD | 0.00% | |
| -0.00USD | 0.00% | |
| -0.00USD | -77.52% | |
| -0.00USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Bone Biologics Stock analysis
Frequently Asked Questions about Bone Biologics stock
EBIT per Share of Bone Biologics is -2.75 USD in 2025.
EBIT per Share of Bone Biologics changed from -1.43 USD to -2.75 USD, representing a 92.78% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Bone Biologics since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Bone Biologics
All Key Metrics — Bone Biologics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth